Intellia Therapeutics Stock In Focus As HAE Gene Editing Wins Priority Review

Simply Wall St.11-14 13:20

Intellia Therapeutics reported third quarter 2026 and year to date net losses while advancing its pipeline, and separately released updated clinical and regulatory milestones for its one time CRISPR ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2683687121?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-11-14 13:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2683687121","market":"hk","top_or_hot":-1,"title":"Intellia Therapeutics Stock In Focus As HAE Gene Editing Wins Priority Review","media":"Simply Wall St.","content":"<div>\n<p>Intellia Therapeutics reported third quarter 2026 and year to date net losses while advancing its pipeline, and separately released updated clinical and regulatory milestones for its one time CRISPR ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-stock-in-focus-as-hae-gene-editing-win\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intellia Therapeutics Stock In Focus As HAE Gene Editing Wins Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntellia Therapeutics Stock In Focus As HAE Gene Editing Wins Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-14 13:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-stock-in-focus-as-hae-gene-editing-win><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intellia Therapeutics reported third quarter 2026 and year to date net losses while advancing its pipeline, and separately released updated clinical and regulatory milestones for its one time CRISPR ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-stock-in-focus-as-hae-gene-editing-win\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z6F94.USD","symbol_name":"Legg Mason Royce - US Smaller Companies A Acc USD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-stock-in-focus-as-hae-gene-editing-win","article_id":"2683687121","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-stock-in-focus-as-hae-gene-editing-win","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2683687121","pubTimestamp":1794633622,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"MMitch LawlerNovember 14, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","HAE":"美国血液技术","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","NTLA":"Intellia Therapeutics Inc","BK4585":"ETF&股票定投概念","BK4198":"医疗保健用品","BK4556":"基因编辑","BK4139":"生物科技","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","BK4535":"淡马锡持仓","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4588":"碎股","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC"},"translate_title":"HAE 基因编辑赢得优先审查，Intellia Therapeutics 股票成为焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1.5,"HAE":1.5},"content_text":"Intellia Therapeutics reported third quarter 2026 and year to date net losses while advancing its pipeline, and separately released updated clinical and regulatory milestones for its one time CRISPR therapies lonvo z in hereditary angioedema and nex z in transthyretin amyloidosis. The combination of a priority FDA review for lonvo z and completion of Phase 3 enrollment for nex z highlights how Intellia Therapeutics is moving from a pure R&D story toward potential commercial execution in two high cost rare disease markets. This article reviews how Intellia Therapeutics' investment narrative is being shaped by lonvo z's priority FDA review and its reported HAE clinical data.  Scan beyond Intellia Therapeutics and line up other rare-disease and biotech prospects with resilient balance sheets using our hand-picked list of solid balance sheet and fundamentals (24 results) for comparison. AdvertisementIntellia Therapeutics Investment Narrative Recap To own Intellia Therapeutics, you need to believe that one-time CRISPR editing for HAE and ATTR can move from trials into repeatable commercial delivery, even while the firm is still loss making. The analyst consensus narrative on Simply Wall St leans on future revenue and earnings expansion, yet the latest quarterly loss of US$127.49 million underlines how dependent the story is on access to capital and careful spend. In the near term, lonvo z approval timing and launch execution look like the key swing factors. Phase 3 nex z outcomes sit close behind. The bigger risk right now is that any safety or regulatory issue for either asset, or payer pushback on high upfront pricing, slows uptake and stretches the cash runway. The recent results do not appear to change that risk reward balance in a major way. The most relevant fresh data point is MAGNITUDE 2 enrollment completion for nex z in ATTRv PN. That trial now moves fully into the follow up and readout phase, which tightens the link between Intellia Therapeutics' day-to-day spending and the timing of a second potential commercial asset behind lonvo z. With around 60 patients, the design is relatively lean, so each data point matters for confidence in liver-directed CRISPR and long-term safety. For you as an investor, that update adds another upcoming catalyst beside lonvo z's FDA decision, without changing the core risk profile outlined earlier. The business is still reporting sizeable net losses over the first nine months of 2026 at US$330.35 million, so progress on nex z is less about near term revenue and more about whether Intellia Therapeutics can build a multi-product rare disease franchise that justifies continuing high R&D and potential future financing. Intellia Therapeutics' narrative projects US$645.2 million revenue and US$118.1 million earnings by 2029, which analysts frame as requiring very large annual revenue growth of 121.3% and an earnings improvement of about US$518.1 million from the current loss of US$400.0 million. Uncover why Intellia Therapeutics' fair value indicates a 138% potential upside to its current price, a gap that could narrow quickly as sentiment catches up. NasdaqGM:NTLA 1-Year Stock Price Chart Exploring Other Perspectives One catalyst that bearish analysts focus on is the risk that Intellia Therapeutics keeps spending heavily while product uptake lags. Before this news, the lowest forecasts were only about US$18.6 million of revenue and US$3.3 million of earnings by 2029. That is far more cautious than consensus; treat this as one viewpoint and explore several others before deciding what feels reasonable to you. Explore 3 other Intellia Therapeutics fair value estimates, including one that suggests it could be worth just $22.78! Form Your Own Verdict Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider conducting your own research and forming an independent view.  A great starting point for your Intellia Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. See our latest analysis for Intellia Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Intellia Therapeutics' overall financial health at a glance.  Looking For More Investment Ideas Beyond Intellia Therapeutics? Once you have a view on Intellia Therapeutics, it can help to benchmark that opinion against other companies with different risk and return profiles. The Simply Wall St Screener lets you scan across sectors and market caps so you can build a watchlist that fits your goals instead of relying on a single high conviction idea.  If you want businesses that trade below what their fundamentals might justify, line up candidates using our 32 high quality undervalued stocks and see how their valuations compare to Intellia Therapeutics. If stability matters most to you, filter for companies with stronger balance sheets and sturdier fundamentals through the 31 resilient stocks with low risk scores to contrast their risk profile with higher volatility biotech names. If you enjoy hunting for earlier stage opportunities, scan a 13 elite penny stocks with strong financials that still show solid financial characteristics and decide which ones, if any, deserve a place on your radar.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2683687121","isCrawlerRequest":true}